Literature DB >> 10091940

Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells.

A B Geldhof1, J Van Ginderachter, P Vandersteen, G Raes, P De Baetselier.   

Abstract

We have previously reported that transfection of mouse interferon gamma (IFN-gamma) in H-2Kk-positive BW variants (BW-Sp3) abolishes tumorigenicity and reduces metastatic capacity. To further increase the immunogenicity of BW-Sp3 cells, the gene for human interleukin 2 (huIL-2) was transfected in these cancer cells. Single BW-Sp3(huIL-2) and double BW-Sp3(huIL-2+IFN-gamma) transfectants were generated and their behavior was investigated as compared to parental and IFN-gamma-transfected BW-Sp3. Although expression of huIL-2 was equally effective as IFN-gamma in preventing tumor formation and reducing experimental metastasis, it did not confer protection to spontaneous metastases and even reversed the anti-metastatic activity of IFN-gamma. Inoculation of the BW variants in immunocompromised mice revealed that expression of IL-2 activates both T cells and aspecific immune effectors. However, in immunocompromised mice a clear pro-metastatic effect of IL-2 was recorded. Analysis of membrane antigens on the different variants showed a selective effect of huIL-2 on the expression of two surface antigens, i.e. L-selectin and metastatic T cell hybridoma antigen (MTH), which may contribute to metastasis. Hence upon expression of huIL-2 in T lymphoma variants, tumor outcome will depend on the balanced effects of the transfected cytokines on the immune response and the redirected effect on tumor progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10091940     DOI: 10.1023/a:1006585525399

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

1.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

Authors:  T Aoki; K Tashiro; S Miyatake; T Kinashi; T Nakano; Y Oda; H Kikuchi; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Identification of T-cell antigens expressed by metastatic T-cell hybridomas and lymphomas.

Authors:  D Van Hecke; H Verschueren; P De Baetselier
Journal:  Int J Cancer       Date:  1990-04-15       Impact factor: 7.396

3.  Direct killing of interleukin-2-transfected tumor cells by human neutrophils.

Authors:  F Pericle; R A Kirken; P K Epling-Burnette; D K Blanchard; J Y Djeu
Journal:  Int J Cancer       Date:  1996-05-03       Impact factor: 7.396

4.  Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.

Authors:  G Richter; S Krüger-Krasagakes; G Hein; C Hüls; E Schmitt; T Diamantstein; T Blankenstein
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

5.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.

Authors:  L D Shultz; P A Schweitzer; S W Christianson; B Gott; I B Schweitzer; B Tennent; S McKenna; L Mobraaten; T V Rajan; D L Greiner
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

6.  Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.

Authors:  A Porgador; R Bannerji; Y Watanabe; M Feldman; E Gilboa; L Eisenbach
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

7.  Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens.

Authors:  T VandenDriessche; M Bakkus; D Toussaint-Demylle; K Thielemans; H Verschueren; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

Review 8.  Cytokine-induced tumor immunogenicity: endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity.

Authors:  R N Apte; A Douvdevani; M Zoller; R M White; T Dvorkin; N Shimoni; E Fima; M Hacham; M Huleihel; D Benharroch
Journal:  Immunol Lett       Date:  1993-12       Impact factor: 3.685

9.  Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.

Authors:  S Silagi; R Dutkowski; A Schaefer
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

10.  Acute myeloid leukaemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor.

Authors:  D Macdonald; Y Z Jiang; D Swirsky; T Vulliamy; R Morilla; J Bungey; A J Barrett
Journal:  Br J Haematol       Date:  1991-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.